Figure 2

Metformin reduced infarct volume and improved neurobehavioral outcomes following transient middle cerebral artery (tMCAO) in mice. (A) Photographs show a series of coronal sections with cresyl violet staining following tMCAO in metformin- and saline-treated mice. (B) Bar graph shows a quantification of the infarct volume from (A). n =6 per group. The changes in neurological scores (C) and the rotarod test (D) at 1, 3, 7 and 14 days following tMCAO in metformin- and saline-treated mice. n =9 per group, data are mean ± SD, *P < 0.05, metformin versus control group, **P < 0.01, metformin versus control group.